CUDC-305
- DEBIO-0932
Axon 3923
CAS:
1061318-81-7
Purity:
99%
- Soluble in DMSO
- MF: C22H30N6O2S
- MW: 442.58
Description
CUDC-305 is an orally bioavailable inhibitor of Heat Shock Proteins, displaying high affinity for HSP90α/β (about 100 nM in IC50) and HSP90 complex derived from cancer cells (IC50= 48.8 nM). Exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 hours) compared with normal tissues. BBB Penetrant.
More Information
| Parent CAS No. | 1061318-81-7 |
|---|---|
| Chemical Name | 2-(6-(Dimethylamino)benzo[d][1,3]dioxol-5-ylthio)-1-(2-(neopentylamino)ethyl)-1H-imidazo[4,5-c]pyridin-4-amine |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | N1C(N)=C2N=C(SC3C=C4OCOC4=CC=3N(C)C)N(CCNCC(C)(C)C)C2=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25) |
| InChiKey | RVJIQAYFTOPTKK-UHFFFAOYSA-N |
| CID | 44156921 |
| Short Description | HSP90 inhibitor |
References
- R Bao et al. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 2009 Dec;8(12):3296-306.
- R Bao R et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009 Jun 15;15(12):4046-57.
Other Categories
Get a Quote for
Loading...